Candriam S.C.A. Vaxcyte, Inc. Transaction History

Candriam S.C.A.

$16.9 Billion
Q4 2024

A detailed history of Candriam S.C.A. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 114,110 shares of PCVX stock, worth $9.1 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

114,110

Holding current value

$9.1 Million

% of portfolio

0.06%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Feb 06, 2025	BUY	$80.97 - $117.93 $9.24 Million - $13.5 Million	114,110 New	114,110 $9.34 Million
Q1 2023 May 12, 2023	BUY	$36.27 - $47.2 $437,778 - $569,704	12,070 New	12,070 $452,000

Others Institutions Holding PCVX

# of Institutions

349

Shares Held

130M

Call Options Held

539K

Put Options Held

253K

Vanguard Group Inc Valley Forge, PA

12M
Shares

$954 Million
0.02% of portfolio
Janus Henderson Group PLC London, X0

10.6M
Shares

$843 Million
0.46% of portfolio
Black Rock Inc. New York, NY

9.94M
Shares

$793 Million
0.02% of portfolio
Ra Capital Management, L.P. Boston, MA

8.69M
Shares

$693 Million
11.52% of portfolio
Capital Research Global Investors Los Angeles, CA

6.21M
Shares

$495 Million
0.11% of portfolio

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $4.73B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account